Blue Lake Biotechnology is developing BLB201 as an intranasal vaccine to prevent acute and severe disease associated with RSV infection. Phase 1 clinical trial results demonstrate BLB201's safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback